arrow
T

Taha Y. Taha

gladstone institutes
H指数:15
被引数:2,047

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Repurposing drug screen for the identification of helicase inhibitors from viruses of pandemic concern

用于识别来自流行病相关病毒解旋酶抑制剂的药物重用筛选

2026-04-290
OAAI
Discovery of Coronavirus Main Protease Inhibitors with Enhanced Brain Exposure and Potent Oral Efficacy in SARS-CoV-2 and MERS Infection Models
2026-01-010
PRE
A non-spike nucleocapsid R204P mutation in SARS-CoV-2 Omicron XEC enhances inflammation and pathogenicity

SARS-CoV-2 Omicron XEC株中一种非刺突核衣壳R204P突变增强了炎症和致病性

2025-12-140
OAAI
Discovery of AVI-6451, a Potent and Selective Inhibitor of the SARS-CoV-2 ADP-Ribosylhydrolase Mac1 with Oral Efficacy In Vivo
2025-12-010
PRE
The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2

Mac1 ADP-核糖基水解酶是SARS-CoV-2的 therapeutic target。

2025-11-191
OA
Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus MPro inhibitors with potent in vivo efficacy

基于结构的具有高生物利用度、共价键、广谱冠状病毒MPro抑制剂的发现,并具有强体内效力

2025-04-250
OA
Enhanced RNA replication and pathogenesis in recent SARS-CoV-2 variants harboring the L260F mutation in NSP6
2025-03-010
OAAI
Torsional twist of the SARS-CoV and SARS-CoV-2 SUD-N and SUD-M domains

SARS-CoV和SARS-CoV-2 SUD-N和SUD-M结构域的扭转扭曲

2025-02-190
OAAI
Fibrin drives thromboinflammation and neuropathology in COVID-19
Nature
IF48.5
2024-08-280
OAAI
Neutralizing and binding antibody responses to SARS-CoV-2 with hybrid immunity in pregnancy
2024-08-270
OAAI
NF-κB inhibitor alpha controls SARS-CoV-2 infection in ACE2-overexpressing human airway organoids
2024-07-041
OAAI
Hepatitis C virus infects and perturbs liver stem cells
MBIO
IF4.7
2023-12-195
OAAI
Previous exposure to Spike-providing parental strains confers neutralizing immunity to XBB lineage and other SARS-CoV-2 recombinants in the context of vaccination
2023-10-311
OAAI
SARS-CoV-2 infection of airway organoids reveals conserved use of Tetraspanin-8 by Ancestral, Delta, and Omicron variants
2023-03-013
OAAI